San Francisco, California – Immumem Therapeutics, a preclinical-stage biotech company engineering next-generation immune cell therapies for solid tumors, today announced that its founder and CEO, Shubhranshu Gupta, PhD, has been profiled in Unicorns Journal, the founder storytelling platform of Unicorns Club.
The feature, titled “Shubh Gupta: Turning Immune Cells into Marathon Runners Against Cancer,” explores Immumem’s vision to engineer durable, “marathon runner” immune cells capable of sustaining activity in the hostile tumor microenvironment, as well as Dr. Gupta’s journey building Immumem at the intersection of synthetic biology, immunology, and computational modeling.
Unicorns Journal is produced by Unicorns Club, a Product Hunt Golden Kitty Award–winning platform that helps early-stage founders share traction and connect with global investors through real-time, transparent storytelling.
“We’re honored to be featured by Unicorns Journal and to share why we believe the next generation of cell therapies must be designed for endurance inside solid tumors, not just potency in a dish,” said Dr. Gupta. “Our work at Immumem is focused on building immune cells that can outlast and outmaneuver the tumor microenvironment, and we’re excited to bring more visibility to that mission through this piece.”
The full interview is available on Unicorns Journal at: https://journal.unicorns.club/journal/shubh-gupta.